

Doc Number: OF-RC-INSP-12B	<b>RAPID ALERT NOTIFICATION FORM</b>	<b>SAHPRA</b> South African Health Products Regulatory Authority
Revision: 1.0		Effective date: 01 December 2023

		<b>Reference Number: Case 63</b>
<b>Rapid Alert Notification of a Quality Defect</b>		
1. To: The Regulatory Authority		
2. Product Recall Classification: <b>Class: II Type: A</b>	3. Falsification / Fraud (specify) Not Applicable	
4. Product: <b>YAZ Plus</b>	5. Marketing Authorisation Number: <b>45/21.8.2/0534</b>	
6. Brand/Trade Name: <b>YAZ Plus</b>	7. INN or Generic Name: <b>Drospirenone + Ethinylestradiol + Levomefolate calcium</b>	
8. Dosage Form: <b>Tablets</b>	9. Strength: <b>24 tablets containing drospirenone 3,0 mg, ethinylestradiol (as betadex clathrate) 0,02 mg plus levomefolate calcium 0,451 mg</b> <b>4 tablets containing levomefolate calcium 0,451 mg</b>	
10. Batch number (and bulk, if different): <b>WEW96J</b>	11. Expiry Date: <b>03/2026</b>	
12. Pack size and Presentation: <b>28's Tablets</b>	13. Date Manufactured: <b>7 – 9 August 2023</b> (packaging date)	
14. Marketing Authorisation Holder (MAH): <b>Bayer (Pty) Ltd, 27 Wrench Road, Isando</b> Contact Person: <b>Mr. Eric Chauke</b> Telephone: <b>011 921 5549</b>		
15.1 Manufacturer: <b>Bayer Weimar GmbH und Co. KG, Döbereinerstr.20, 99427 Weimar, Germany</b>	16. Recalling Firm (if different from 15.1):  <b>Bayer (Pty) Ltd, 27 Wrench Road,  Isando</b>  Contact Person: <b>Mr. Eric Chauke</b>  Telephone: <b>011 921 5549</b>	
15.2 Where the defect is attributed to a manufacturing site, site where defect occurred (if different from 15.1):  Not Applicable		
17. Recall Number Assigned (if available): Not applicable		

<b>Doc Number:</b> OF-RC-INSP-12B	<b>RAPID ALERT NOTIFICATION FORM</b>	
Revision: 1.0		Effective date: 01 December 2023

18. Summary of Quality Defect and Reason for Recall:

This recall is initiated due to a limited number of packs found in retail Pharmacy, with mix-up of the sequence of hormone-containing and hormone-free tablets, wherein some packs had

- 24 light orange hormone-free, and
- 4 pink film-coated hormone tablets

Instead of

- 24 pink film-coated hormone tablets and
- 4 light orange hormone-free tablets.

---

19. Distribution including export to other markets:  
 According to the MAH, distribution of the affected batch was as follows:  
**Botswana** = 115 units, **Namibia** = 1 472 units, **Mauritius** = 1 500 units, **Zimbabwe** = 200 units and **Lesotho** = 100 units  
 For more information about exporting or batch destination, please contact Marketing Authorisation Holder and/ or local Regulatory Authority (SAHPRA) [tsakane.mashaba@sahpra.org.za](mailto:tsakane.mashaba@sahpra.org.za) and [mokgadi.fafudi@sahpra.org.za](mailto:mokgadi.fafudi@sahpra.org.za) then copy [deon.poovan@sahpra.org.za](mailto:deon.poovan@sahpra.org.za)

---

20. Action taken by Issuing Authority: Conduct a recall (**Class II, Type A**)  
 The information is published on the SAHPRA recall webpage <https://www.sahpra.org.za/product-recalls/>

---


21. Proposed Action: SAHPRA is monitoring the recall.

---

22. From (Issuing Authority):

South Africa Health Products Regulatory Authority (SAHPRA) Loftus Park, Building A, 402 Kirkness St, Arcadia, Pretoria, 0083, South Africa.

Deon Poovan – Acting Chief Regulatory Officer  
 Email: [deon.poovan@sahpra.org.za](mailto:deon.poovan@sahpra.org.za) Tel: +27 65 683 9783  
 Mokgadi Fafudi – Manager: Regulatory Compliance  
 Email: [mokgadi.fafudi@sahpra.org.za](mailto:mokgadi.fafudi@sahpra.org.za) Tel: +27 66 301 1878

Signed:  Date: \_\_\_\_\_

Deon Poovan – Acting Chief Regulatory Officer

<b>Doc Number:</b> OF-RC-INSP-12B	<b>RAPID ALERT NOTIFICATION FORM</b>	 South African Health Products Regulatory Authority
Revision: 1.0		Effective date: 01 December 2023

Approved for use!